CompletedNot Applicable

Incidence of Invasive Pulmonary Aspergillosis in Ventilator-associated Pneumonia

France263 participantsStarted 2023-08-28

Plain-language summary

Mechanically ventilated patients are at risk of developing ventilator-associated pneumonia (VAP). Invasive pulmonary aspergillosis (IPA), the diagnosis of which motivates the implementation of specific treatments, is one of the causes of VAP. The hypothesis of the study is that the incidence of IPA is 12.4%. For each patient presenting with a suspicion of VAP and requiring a bronchoalveolar lavage (BAL), the diagnosis of API will be evaluated by biological examinations performed on blood and BAL. Medical and surgical history as well as clinical and biological data will be collected for 28 days or until discharge from the ICU.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patient (age ≥ 18 years), * On invasive ventilation for more than 48 hours, * Suspected VAP, defined by the appearance or worsening of a radiological pulmonary infiltrate, associated with 2 of the following clinical criteria: * Fever ≥ 38° C or hypothermia ≤ 36.5° C * Leukocytes \> 12x109 or \< 4x109/L * Purulent tracheal secretions Exclusion Criteria: * Neutropenic patients (neutrophils \< 0.5G/L), * Previous diagnosis of IPA, * Minor patients.

What they're measuring

Incidence of probable or proven IPA according to the Verweij criteria in patients with suspected VAP

Timeframe: On the 1 day of inclusion

Trial details

NCT IDNCT05671328

SponsorUniversity Hospital, Lille

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-07-18

View on ClinicalTrials.gov More Ventilator Associated Pneumonia trials